In more than 70 countries, Médecins Sans Frontières provides medical humanitarian assistance to save lives and ease the suffering of people in crisis situations.
We set up the MSF Access Campaign in 1999 to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostic tests and vaccines for people in our programmes and beyond.
Based in Paris, CRASH conducts and directs studies and analysis of MSF actions. They participate in internal training sessions and assessment missions in the field.
Based in Geneva, UREPH (or Research Unit) aims to improve the way MSF projects are implemented in the field and to participate in critical thinking on humanitarian and medical action.
Based in Brussels, MSF Analysis intends to stimulate reflection and debate on humanitarian topics organised around the themes of migration, refugees, aid access, health policy and the environment in which aid operates.
This logistical and supply centre in Brussels provides storage of and delivers medical equipment, logistics and drugs for international purchases for MSF missions.
This supply and logistics centre in Bordeaux, France, provides warehousing and delivery of medical equipment, logistics and drugs for international purchases for MSF missions.
This logistical centre in Amsterdam purchases, tests, and stores equipment including vehicles, communications material, power supplies, water-processing facilities and nutritional supplements.
SAMU provides strategic, clinical and implementation support to various MSF projects with medical activities related to HIV and TB. This medical unit is based in Cape Town, South Africa.
BRAMU specialises in neglected tropical diseases, such as dengue and Chagas, and other infectious diseases. This medical unit is based in Rio de Janeiro, Brazil.
Our medical guidelines are based on scientific data collected from MSF’s experiences, the World Health Organization (WHO), other renowned international medical institutions, and medical and scientific journals.
Providing epidemiological expertise to underpin our operations, conducting research and training to support our goal of providing medical aid in areas where people are affected by conflict, epidemics, disasters, or excluded from health care.
Evaluation Units have been established in Vienna, Stockholm, and Paris, assessing the potential and limitations of medical humanitarian action, thereby enhancing the effectiveness of our medical humanitarian work.
The Luxembourg Operational Research (LuxOR) unit coordinates field research projects and operational research training, and provides support for documentation activities and routine data collection.
The MSF Paediatric Days is an event for paediatric field staff, policy makers and academia to exchange ideas, align efforts, inspire and share frontline research to advance urgent paediatric issues of direct concern for the humanitarian field.
The MSF Foundation aims to create a fertile arena for logistics and medical knowledge-sharing to meet the needs of MSF and the humanitarian sector as a whole.
A collaborative, patients’ needs-driven, non-profit drug research and development organisation that is developing new treatments for neglected diseases, founded in 2003 by seven organisations from around the world.
Eswatini (former Swaziland) has one of the world’s highest rates of HIV, with nearly one in three adults living with the disease. However, around 80 per cent of people with TB in Eswatini are HIV positive.
Estimates suggest that HIV incidence rates in Eswatini have fallen in recent years, as significant progress has been made in improving the number of people receiving antiretroviral (ARV) treatment.
In addition, the incidence of drug-sensitive TB has more than halved between 2010 and 2016, as numbers of people with drug-resistant forms of TB have fallen by 20 per cent between 2015 and 2016.
We continue to help more HIV patients access ARV treatment through the ’test and start’ strategy. A team has been piloting ‘test and start’ in the Nhlangano project; after HIV testing, ARV treatment was offered to more than 1,700 people after a positive HIV diagnosis to immediately start treatment.
We now treat patients with extensively drug-resistant TB (XDR-TB), and those developing severe side effects, using the promising new drugs bedaquiline and delamanid in combination with repurposed drugs.
In 2018
6,230
6,23
people on first-line ARV treatment
610
61
people on second- and third-line ARV treatment
580
58
people started on treatment for TB, including 100 for DR-TB
HIV/AIDS
AIDS death toll stagnating due to lack of testing at community level
Press Release1 Dec 2019
HIV/AIDS
MSF report "No time to lose" examines the fight against AIDS in 15 countries
Report27 Nov 2019
Eswatini (formerly Swaziland)
MSF hands over its Manzini project, while continuing activities in Shiselweni
Statement25 Jun 2018
Eswatini (formerly Swaziland)
"A long and gruelling seven years and now it is over"
Voices from the Field29 Jun 2017
Eswatini (formerly Swaziland)
For patients with XDR-TB, treatment is a gruelling journey with severe side effects
Voices from the Field27 Feb 2017
HIV/AIDS
MSF calls for quality HIV care in neglected communities
Press Release18 Jul 2016
2007
2007
Year MSF first worked in the country
Related topics
Medical Activities
HIV/AIDS
Nearly 800,000 people die each year from HIV/AIDS, while nearly 2 million people become newly infected with the virus.
Medical Activities
Tuberculosis
Tuberculosis (TB) is one of the world’s biggest global health crises. Killing 1.5 million people in 2018, TB is the world’s deadliest infectious disease (WHO).
